Genetics of host response in leprosy

Leprosy Review

Volumn 77, Issue 3, 2006, Pages 189-202

  Moraes, Milton Ozório ^a   Cardoso, Cynthia Chester ^a   Vanderborght, Patrícia Rosa ^a   Pacheco, Antônio Guilherme ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; LYMPHOTOXIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; PARKIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

CHROMOSOME ANALYSIS; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC LINKAGE; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; GENOMICS; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; LEPROSY; MARKER GENE; MYCOBACTERIUM LEPRAE; OUTCOME ASSESSMENT; PHENOTYPE; PROGNOSIS; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOKINES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; LEPROSY; LYMPHOTOXIN-ALPHA; RECEPTORS, CALCITRIOL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845430507     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Monot M, Honore N, Garnier T et al. On the origin of leprosy. Science, 2005; 308: 1040-1042.
2. Moet FJ, Pahan D, Schuring RP et al. Physical distance, genetic relashionship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis, 2006; 193: 346-353.
3. Beiguelman B. Some remarks on the genetics of leprosy resistance. Acta Genet Med Gemello, 1968; 17: 584-594.
4. Krutzik SR, Tan B, Li H et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med, 2005; 11: 653-660.
5. Verreck FA, de Boer T, Langenberg DM et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA, 2004; 101: 4560-4565.
6. Van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis, 2004; 4: 739-749.
7. Keane J. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis, 2004; 39: 300-302.
8. Joyce MP, Scollard DM. Borderline lepromatous leprosy in a patient treated with infliximab (a tumor necrosis factor inhibitor). In: Proceedings of the 16th International Leprosy Congress, Salvador, Brazil, 2002, p. 145.
9. Daly AK. Candidate gene case-control studies. Pharmacogenomics, 2003; 4: 127-139.
10. Rothman KJ, Greenland S, Modern epidemiology Lippincott-Raven, Philadelphia 1998.
11. Schaid DJ, Rowland CM, Tines DE et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet, 2002; 70: 425-434.
12. Rajalingam R, Singal DP, Mehra NK. Transporter associated with antigen-processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis. Tissue Antigens, 1997; 49: 168-172.
13. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol, 1993; 11: 403-450.
14. Gorodezky C, Alaez C, Munguia A et al. Molecular mechanisms of MHC linked susceptibility in leprosy: towards the development of synthetic vaccines. Tuberculosis, 2004; 84: 82-92.
15. Wang LM, Kimura A, Satoh M, Mineshita S. HLA linked with leprosy in southern China: HLA-linked resistance alleles to leprosy. Int J Lepr Other Mycobact Dis, 1999; 67: 403-408.
16. Shankarkumar U, Ghosh K, Badakere S, Mohanty D. Novel HLA class I alleles associated with Indian leprosy patients. J Biomed Biotechnol, 2003; 2003: 208-211.
17. De Vries RR, Mehra MK, Vaidya MC et al. HLA-linked control of susceptibility to tuberculoid leprosy and association with HLA-DR types. Tissue Antigens, 1980; 16: 89-112.
18. Rani R, Fernandez-Vina MA, Zaheer SA et al. Study of HLA class II alleles by PCR oligotyping in leprosy patients from north India. Tissue Antigens, 1993; 42: 133-137.
19. Schauf V, Ryan S, Scollard D et al. Leprosy associated with HLA-DR2 and DQw1 in the population of northern Thailand. Tissue Antigens, 1985; 26: 243-247.
20. Visentainer JE, Tsuneto LT, Serra MF et al. Association of leprosy with HLA-DR2 in a Southern Brazilian population. Braz J Med Biol Res, 1997; 30: 51-59.
21. van Eden W, de Vries RR, D'Amaro J et al. HLA-DR-associated genetic control of the type of leprosy in a population from surinam. Hum Immunol, 1982; 4: 343-350.
22. Gorodezky C, Flores J, Arevalo N et al. Tuberculoid leprosy in Mexicans is associated with HLA-DR3. Lepr Rev, 1987; 58: 401-406.
23. Rani R, Mukherjee R, Stastny P. Diversity of HLA-DR2 in North Indians: the changed scenario after the discovery of DRB1*1506. Tissue Antigens, 1998; 52: 147-152.
24. Groves RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. Proc Natl Acad Sci USA, 1995; 92: 11874-11878.
25. Kindler V, Sappino AP, Grau GE et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell, 1989; 56: 731-740.
26. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun, 2004; 5: 315-329.
27. Roy S, McGuire W, Mascie-Taylor CG et al. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis, 1997; 176: 530-532.
28. Santos AR, Almeida AS, Suffys PN et al. Tumor necrosis factor promoter polymorphism (TNF2) seems to protect against development of severe forms of leprosy in a pilot study in Brazilian patients. Int J Lepr Other Mycobact Dis, 2000; 68: 325-327.
29. Santos AR, Suffys PN, Vanderborght PR et al. Role of tumor necrosis factor-a and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis, 2002; 186: 1687-1691.
30. Shaw MA, Donaldson IJ, Collins A et al. Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes Immun, 2001; 2: 196-204.
31. Fitness J, Floyd S, Warndorff DK et al. Large-scale candidate gene study of leprosy susceptibility in the Karonga district of Northern Malawi. Am J Trop Med Hyg, 2004; 71: 330-340.
32. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-a gene that are associated with susceptibility to myocardial infarction. Nat Genet, 2002; 32: 650-654.
33. Moraes MO, Duppre NC, Suffys PN et al. Tumor necrosis factor-α promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of bordeline tuberculoid leprosy patients. Immunogenetics, 2001; 53: 45-47.
34. Vanderborght PR, Matos HJ, Salles AM et al. Single nucleotide polymorphisms (SNPs) at -238 and -308 positions in the TNFalpha promoter: clinical and bacteriological evaluation in leprosy. Int J Lepr Other Mycobact Dis, 2004; 72: 143-148.
35. Volk H, Asadullah K, Gallagher G et al. IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol, 2001; 22: 414-417.
36. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med, 1995; 181: 839-844.
37. Lima MC, Pereira GM, Rumjanek FD et al. Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol, 2000; 51: 419-428.
38. Moraes MO, Pacheco AG, Schonkeren JJ et al. Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun, 2004; 5: 592-595.
39. Malhotra D, Darvishi K, Sood S et al. IL-10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy. Hum Genet, 2005; 118: 295-300.
40. Mörmann M, Rieth H, Hua TD et al. Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun, 2004; 5: 246-255.
41. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol. Clin Exp Immunol, 1991; 84: 200-206.
42. Roy S, Frodsham A, Saha B et al. Association of vitamin D receptor genotype with leprosy type. J Infect Dis, 1999; 179: 187-191.
43. Abel L, Sanchez FO, Oberti J et al. Susceptibility to leprosy is linked to the human NRAMP1 gene. J Infect Dis, 1998; 177: 133-145.
44. Meisner SJ, Mucklow S, Warner G et al. Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in west africans. Am J Trop Med Hyg, 2001; 65: 733-735.
45. Alcaïs A, Sanchez FO, Thuc NV et al. Granulomatous reaction to intradermal injection of lepromin (mitsuda reaction) is linked to the human NRAMP1 gene in Vietnamese leprosy sibships. J Infect Dis, 2000; 181: 302-308.
46. Ferreira FR, Goulart LR, Silva HD, Goulart IMB. Susceptibility to leprosy may be conditioned by an interaction between the NRAMP1 promoter polymorphisms and the lepromin response. Int J Lepr Other Mycobact Dis, 2004; 72: 457-467.
47. Ohyama H, Ogata K, Takeuchi K et al. Polymorphism of the 5′ flanking region of the IL-12 receptor beta2 gene partially determines the clinical types of leprosy through impaired transcriptional activity. J Clin Pathol, 2005; 58: 740-743.
48. Wibawa T, Soebono H, Matsuo M. Association of a missense mutation of the laminin-α2 gene with tuberculoid type of leprosy in Indonesian patients. Trop Med Int Health, 2002; 7: 631-636.
49. Kang TJ, Lee SB, Chae GT. A polymorphism in the Toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine, 2002; 20: 55-62.
50. Malhotra D, Relhan V, Reddy BSN, Bamezai R. TLR2 Arg677Trp polymorphism in leprosy: revisited. Hum Genet, 2005; 116: 413-415.
51. Lee SB, Kim BC, Jin SH et al. Missense mutations of the interleukin-12 receptor beta 1(IL12RB1) and interferon-gamma receptor 1 (IFNGR1) genes are not associated with susceptibility to lepromatous leprosy in Korea. Immunogenetics, 2003; 55: 177-181.
52. Siddiqui MR, Meisner S, Tosh K et al. A major susceptibility locus for leprosy on chromosome 10p13. Nat Genet, 2001; 27: 439-441.
53. Tosh K, Meisner S, Siddiqui MR et al. A region of chromosome 20 is linked to leprosy susceptibility in a South Indian population. J Infect Dis, 2002; 186: 1190-1193.
54. Mira MT, Alcaïs A, Van Thuc N et al. Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. Nat Genet, 2003; 33: 412-415.
55. Mira MT, Alcaïs A, VanThuc N et al. Susceptibility to leprosy is associated with PARK2 e PACRG. Nature, 2004; 427: 636-640.
56. Malhotra D, Darvishi K, Lohra M et al. Association study of major risk single nucleotide polymorphisms in the common regulatory region of PARK2 and PACRG genes with leprosy in an Indian population. Eur J Hum Genet, 2005 Dec 14; [Epub ahead of print].
57. Matsumine H, Saito M, Shimoda-Matsubayashi S et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25·2-27. Am J Hum Genet, 1997; 60: 588-596.
58. Shimura H, Hattori N, Kubo S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature, 2000; 25: 302-305.
59. Miller EN, Jamieson SE, Joberty C et al. Genome-wide scans for leprosy and tuberculosis susceptibility genes in Brazilians. Genes Immun, 2004; 5: 63-67.
60. Jamieson SE, Miller EN, Black GF et al. Evidence for a cluster of genes on chromosome 17q11-q21 controlling susceptibility to tuberculosis and leprosy in Brazillians. Genes Immun, 2004; 5: 46-57.
61. Shin HD, Park BL, Kim YH et al. Common interleukin 10 polymorphism associated with decreased risk of tuberculosis. Exp Mol Med, 2005; 37: 128-132.
62. Greenwood CM, Fujiwara TM, Boothroyd LJ et al. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am J Hum Genet, 2000; 67: 405-416.
63. Jardim MR, Antunes SL, Simons B et al. Role of PGL-I antibody detection in the diagnosis of pure neural leprosy. Lepr Rev, 2005; 76: 232-240.